Penserra Capital Management LLC Exelixis, Inc. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $273,895 - $363,727	-15,705 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $267,456 - $356,032	15,705 New	15,705 $356,000
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $48,586 - $65,521	-2,642 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$20.67 - $26.94 $54,610 - $71,175	2,642 New	2,642 $64,000
Q1 2019 May 08, 2019	SELL	$19.6 - $24.76 $108,486 - $137,046	-5,535 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$13.65 - $21.8 $75,552 - $120,663	5,535 New	5,535 $108,000
Q1 2018 May 08, 2018	SELL	$22.15 - $31.89 $20,245 - $29,147	-914 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$24.23 - $30.93 $22,146 - $28,270	914	914 $27,000

518

243M

2.84M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.